Leukotrienes as Modifiers of Preclinical Atherosclerosis?
Preclinical atherosclerosis represents a crucial period associated with several pathophysiological reactions in the vascular wall. Failure to diagnose preclinical atherosclerosis at this stage misses a major opportunity to prevent the long-term consequences of this disease. Surrogate biological and...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/490968 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563160691769344 |
|---|---|
| author | Graziano Riccioni Magnus Bäck |
| author_facet | Graziano Riccioni Magnus Bäck |
| author_sort | Graziano Riccioni |
| collection | DOAJ |
| description | Preclinical atherosclerosis represents a crucial period associated with several pathophysiological reactions in the vascular wall. Failure to diagnose preclinical atherosclerosis at this stage misses a major opportunity to prevent the long-term consequences of this disease. Surrogate biological and structural vascular markers are available to determine the presence and the extension of preclinical vascular injury in the general population. Examples of surrogate markers are carotid intima media thickness and biomarkers including high-sensitivity C-reactive protein, cell adhesion molecules and matrix metalloproteinases, and leukotrienes. Recently, leukotrienes have been implicated as mediators, biomarkers, and possible therapeutic targets in the context of subclinical atherosclerosis. The aim of this short paper is to focus on the relation between preclinical atherosclerosis and leukotrienes, with particular attention to the recent development on the use of leukotriene modifiers in the treatment of atherosclerosis. |
| format | Article |
| id | doaj-art-7a0425a984144fb49939e422f21ae5aa |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-7a0425a984144fb49939e422f21ae5aa2025-02-03T01:20:49ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/490968490968Leukotrienes as Modifiers of Preclinical Atherosclerosis?Graziano Riccioni0Magnus Bäck1Cardiology Unit, San Camillo de Lellis Hospital, Manfredonia, Foggia, ItalyDepartment of Cardiology and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, SwedenPreclinical atherosclerosis represents a crucial period associated with several pathophysiological reactions in the vascular wall. Failure to diagnose preclinical atherosclerosis at this stage misses a major opportunity to prevent the long-term consequences of this disease. Surrogate biological and structural vascular markers are available to determine the presence and the extension of preclinical vascular injury in the general population. Examples of surrogate markers are carotid intima media thickness and biomarkers including high-sensitivity C-reactive protein, cell adhesion molecules and matrix metalloproteinases, and leukotrienes. Recently, leukotrienes have been implicated as mediators, biomarkers, and possible therapeutic targets in the context of subclinical atherosclerosis. The aim of this short paper is to focus on the relation between preclinical atherosclerosis and leukotrienes, with particular attention to the recent development on the use of leukotriene modifiers in the treatment of atherosclerosis.http://dx.doi.org/10.1100/2012/490968 |
| spellingShingle | Graziano Riccioni Magnus Bäck Leukotrienes as Modifiers of Preclinical Atherosclerosis? The Scientific World Journal |
| title | Leukotrienes as Modifiers of Preclinical Atherosclerosis? |
| title_full | Leukotrienes as Modifiers of Preclinical Atherosclerosis? |
| title_fullStr | Leukotrienes as Modifiers of Preclinical Atherosclerosis? |
| title_full_unstemmed | Leukotrienes as Modifiers of Preclinical Atherosclerosis? |
| title_short | Leukotrienes as Modifiers of Preclinical Atherosclerosis? |
| title_sort | leukotrienes as modifiers of preclinical atherosclerosis |
| url | http://dx.doi.org/10.1100/2012/490968 |
| work_keys_str_mv | AT grazianoriccioni leukotrienesasmodifiersofpreclinicalatherosclerosis AT magnusback leukotrienesasmodifiersofpreclinicalatherosclerosis |